Senores Pharmaceuticals Share Price, IPO Listing Highlights: The IPO was listed at a premium of 53% on NSE at Rs 600 on December 30. The IPO was subscribed to a total of 97.86 times. The retail portion was booked 93.16 times and the NIIs booked it 100.35 times. The QIBs subscribed to the issue 97.84 times.
Senores Pharmaceuticals IPO raised Rs 582.11 crore via a combination of a fresh issue and an offer for sale. The IPO bidding was started on December 20 and ended on December 24. The allotment of shares was finalized on December 26. The IPO price band was fixed between Rs 372 to Rs 391 per equity share. Equirus Capital, Ambit, and Nuvama Wealth Management were the book-running lead managers of the IPO, while Link Intime India worked as the registrar for the issue.
Senores Pharmaceuticals Share Price Today, IPO Listing Highlights
Senores Pharmaceuticals Share Price IPO Listing Live Updates: Stocks fall 10%
The stock of Senores Pharmaceuticals has fallen as much 10.2% to an intra-day low of Rs 538.85 after listing at a strong premium. The IPO shares were listed at a price of Rs 600 on the National Stock Exchange, a premium of 53% to the issue price.
Senores Pharmaceuticals Share Price IPO Listing Live Updates: Stock extends loss
Shares of Senores Pharmaceuticals extend losses after listing. The stock fell 9.7% to Rs 541.45 after listing at a premium. The IPO shares were listed on December 30. The stock of Senores Pharma made a strong debut at a premium of 53% to the issue price on NSE.
Senores Pharmaceuticals Share Price IPO Listing Live Updates: Stocks fall 5.6%
The stock of Senores Pharmaceuticals fell 5.6% to an itra-day low of Rs 566.20 after listing at a premium on NSE and BSE. The stock was listed at Rs 600, a premium of 53% to the issue price.
Senores Pharmaceuticals Share Price IPO Listing Live Updates: Lists at 53% premium
Senores Pharmaceuticals was listed at Rs 600 on the National Stock Exchange, a premium of 53.4% to the issue price. It was listed at Rs 593.7 on BSE, a premium of 51.8% to the issue price.
Read more: Senores Pharma makes strong debut; lists over 53% premium on NSE
Senores Pharmaceuticals Share Price IPO Listing Live Updates: Reliance Sec on IPO
“Senores Pharmaceuticals has adopted an inorganic growth through synergistic acquisitions, enhancing market share in USA and regulated markets, alliances for CMO/CDMO business, professional and dedicated management team for diverse business verticals augurs well for the company in the long term. Hence, we recommend a Subscribe to the issue,” said Reliance Securities in an IPO note.
Senores Pharmaceuticals Share Price IPO Listing Live Updates: About Senores Pharma
Senores Pharmaceuticals has a distinct specialty and complex product portfolio for regulated markets, strong R&D capabilities to build differentiated portfolio products and commercialize them with higher market penetration establishing a strong foothold through a long-term marketing arrangement earning revenue growth in the form of licensing fees, transfer pricing and profit sharing.
Senores Pharmaceuticals Share Price IPO Listing Live Updates: GMP update
The stock of Senores Pharmaceuticals was fetching a premium of more than 72% in the grey market, indicating that the stock might list around a price of Rs 72.63. The grey market is an unofficial place to trade shares.